# US 2013/0156703 A1 · Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156703 A1
- Document ID: US20130156703A1
- Status: Published application
- Kind: A1
- Application number: 13/769,095
- Filed: 2013-02-15
- Published: 2013-06-20
- Earliest claimed: 2009-11-06
- Inventors: Fang Fang; David Wurtman; Ron Moss; Michael Malakhov
- Web page: https://patentgrep.com/patent/US20130156703A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/12: Mucolytics
- A61P 25/32: Alcohol-abuse
- A61P 31/06: for tuberculosis
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 9/2477: {Hemicellulases not provided in a preceding group}
- C12Q 1/34: involving hydrolase
- C12Y 302/01018: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- C07K 2319/00: Fusion polypeptide
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

## Claims

### Claim 1

A method of reducing the quantity or level of mucus or preventing an increase in the quantity or level of mucus in a respiratory tract of a subject, the method comprising:
administering to the subject a compound or composition comprising a therapeutically effective amount of a fusion protein, wherein
the fusion protein comprises at least one catalytic domain of a sialidase, wherein the catalytic domain of the sialidase comprises the sequence of amino acids extending from amino acid 274 to amino acid 666 of SEQ ID NO:12, inclusive, and at least one anchoring domain, wherein the anchoring domain is a glycosaminoglycan (GAG) binding domain of human amphiregulin comprising the amino acid sequence of SEQ ID NO:7; and
the therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition further comprises one or more additional compounds.

### Claim 3 (depends on 2)

The method of claim 2, wherein the one or more additional compounds comprises MgSO4 or an analog thereof

### Claim 4 (depends on 2)

The method of claim 2, wherein the one or more additional compounds comprises CaCl2 or an analog thereof.

### Claim 5 (depends on 2)

The method of claim 2, wherein the one or more additional compounds comprises Histidine or an analog thereof

### Claim 6 (depends on 2)

The method of claim 2, wherein the one or more additional compounds comprises Histidine-HCl or an analog thereof.

### Claim 7 (depends on 2)

The method of claim 2, wherein the one or more additional compounds comprises Trehalose or an analog thereof

### Claim 8 (depends on 2)

The method of claim 2, wherein the one or more additional compounds comprises MgSO4, CaCl2, Histidine, Histine-HCl and Trehalose.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound or composition is formulated as a spray.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound or composition is formulated as an inhalant.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound or composition is formulated as a solution for injection.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound or composition is formulated as a cream, salve, gel, or ointment.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound or composition is formulated as a pill, tablet, lozenge, suspension, or solution that can be administered orally.

### Claim 14 (depends on 1)

The method of claim 1, wherein said administration is by use of a nasal spray.

### Claim 15 (depends on 1)

The method of claim 1, wherein said administration is by use of an inhaler.

### Claim 16 (depends on 1)

The method of claim 1, wherein said administration is performed from once to four times a day.

### Claim at position 17

-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the subject has one or more of the following conditions: chronic obstructive pulmonary disease (COPD), bronchitis, bronchiectasis, cystic fibrosis (CF), vasculitis, mucus plugging, Wegener's granulomatosis, pneumonia, tuberculosis, cancer involving the lungs or the respiratory tract, Kartagener syndrome, Young's syndrome, chronic sinopulmonary infection, alpha 1-antitrypsin deficiency, primary immunodeficiency, acquired immune deficiency syndrome, opportunistic infection, an infectious state, a post infectious state, common cold, exercise induced hypersecretion of mucus, inflammatory bowel disease, ulcerative colitis, Crohn's disease, respiratory infection, respiratory obstruction, inhalation or aspiration of a toxic gas, pulmonary aspiration, or alcoholism.

### Claim 23 (depends on 1)

The method of claim 1, wherein the fusion protein has the sequence set forth in SEQ ID NO:21.

### Claim 24

A method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract, comprising:
administering to the subject a compound or composition comprising a therapeutically effective amount of a peptide comprising a sialidase or an active portion thereof and, optionally, an anchoring domain, wherein
the therapeutically effective amount comprises an amount of the peptide that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

### Claim at position 21

-51. (canceled)

### Claim 52

A method of limiting an increase in the quantity of mucus in the respiratory tract of a subject above a baseline level of mucus in said subject's respiratory tract, comprising:
administering to the subject a compound or composition comprising a therapeutically effective amount of a fusion protein, wherein
the fusion protein comprises at least one catalytic domain of a sialidase, wherein the catalytic domain of the sialidase comprises the sequence of amino acids extending from amino acid 274 to amino acid 666 of SEQ ID NO:12, inclusive, and at least one anchoring domain, wherein the anchoring domain is a glycosaminoglycan (GAG) binding domain of human amphiregulin comprising the amino acid sequence of SEQ ID NO:7; and
the therapeutically effective amount comprises an amount of the fusion protein that limits an increase in the quantity of mucus in the respiratory tract of said subject above a baseline level after administration of the compound or composition.

### Claim at position 23

-74. (canceled)

### Claim 75

A method of limiting an increase in the quantity of mucus in the respiratory tract of a subject above a baseline level of mucus in said subject's respiratory tract, comprising:
administering to the subject a compound or composition containing a therapeutically effective amount of a peptide comprising a sialidase or an active portion thereof and, optionally, an anchoring domain, wherein
the therapeutically effective amount comprises an amount of the peptide that limits an increase in the quanitity of mucus in the respiratory tract of said subject above a baseline level after administration of the compound or composition.

### Claim at position 25

-112. (canceled)

### Claim 113

A method, comprising:
(a) administering a collection of compounds or compositions comprising sialidase(s) and/or catalytically active portion(s) thereof to an animal model of asthma;
(b) quantitating the level of mucus in the lung of the animal;
(c) comparing the level measured in (b) with the level of mucus in the lung of the animal prior to administering the collection of compounds or compositions; and
(d) identifying or selecting a compound or composition that reduces the level of mucus relative to the level of mucus in the absence of the compound or composition.

### Claim 114

A method, comprising:
(a) administering a compound or composition comprising a sialidase and/or a catalytically active portion thereof to an animal model of asthma;
(b) quantitating the level of mucus in the lung of the animal;
(c) comparing the level measured in (b) with the level of mucus in the lung of the animal prior to administering the collection of compounds or compositions; and
(d) identifying whether the compound or composition reduces the level of mucus relative to the level of mucus in the absence of the compound or composition.

### Claim 115

A method of assessing whether a compound or composition comprising a sialidase and/or catalytically active portion thereof reduces the quantity of mucus in the respiratory tract of a subject, comprising:
(a) contacting the muscarinic receptors of an animal subject with a compound or composition comprising a sialidase and/or a catalytically active portion thereof;
(b) administering a muscarinic receptor agonist to the subject;
(c) quantitating the airway resistance in the subject;
(d) comparing the airway resistance level measured in (c) with the airway resistance in the absence of contact with the compound or composition;
(e) identifying whether the compound or composition reduces the airway resistance relative to the airway resistance in the absence of contact with the compound or composition; and
(f) if the compound or composition reduces the airway resistance as determined in (e), assessing the compound or composition as one that reduces the quantity of mucus in the respiratory tract of the subject.
